Biogen and Eisai Announce FDA ’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

CAMBRIDGE, Mass. and TOKYO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the Biologics...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news